Scientists have discovered that some tiny segments of RNA thought to be junk instead have a functional role in suppressing ...

A high-quality genome assembly of Silene latifolia was generated by researchers at CNRS/Université Claude Bernard Lyon 1 and ...

Vimentin is a type III intermediate filament (IF) protein normally expressed in cells that develop into connective tissue, blood vessels, and lymphatic tissue (mesenchymal cells). Despite being widely ...

PASADENA, CA, USA I 10 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement ...

The global RNA based therapeutic market size is calculated at USD 9.46 billion in 2025 and is expected to reach around USD 40 ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...

Discover how heart centers across the country are improving patient outcomes and reducing mortality rates through innovative approaches and advanced therapies.

Gaining control of the genetic blueprint of life has been something that comic book and science fiction writers have dreamed ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.